Prognostic implication of aberrant promoter hypermethylation of CpG islands in adenocarcinoma of the lung  by Kim, Young Tae et al.
General Thoracic Surgery Kim et al
G
TSPrognostic implication of aberrant promoter
hypermethylation of CpG islands in adenocarcinoma of the
lung
Young Tae Kim, MD, PhD,a Sun Jung Park, MS,a Seung Hee Lee, BS,a Hee Jung Kang, MD, PhD,bSeokyung Hahn, PhD,c Chang Hyun Kang, MD,a Sook Whan Sung, MD, PhD,a and Joo Hyun Kim, MD, PhDaFrom the Department of Thoracic and Car-
diovascular Surgery, Seoul National Univer-
sity Hospital, and the Cancer Research Insti-
tute, Xenotransplantation Research Center,
Seoul National University College of Medi-
cine, Seoul, Korea; the Department of Lab-
oratory Medicine, Hallym University Col-
lege of Medicine, Anyang, Korea; and the
Medical Research Collaborating Center,
Seoul National University Hospital, Seoul
National University College of Medicine,
Seoul, Korea.
Partially supported by grant 05-2001-003-0
from the Seoul National University Hospi-
tal Research Fund and Sang Koo Hahn Re-
search Fund.
Read at the Eighty-fifth Annual Meeting of
The American Association for Thoracic
Surgery, San Francisco, Calif, April 10-13,
2005.
Received for publication April 7, 2005; re-
visions received April 28, 2005; accepted
for publication June 7, 2005.
Address for reprints: Young Tae Kim, MD,
PhD, Thoracic and Cardiovascular Surgery,
Seoul National University Hospital, 28
Yongun-Dong, Chongno-Ku, Seoul, 110-
744, Republic of Korea (E-mail: ytkim@
snu.ac.kr)
J Thorac Cardiovasc Surg 2005;130:1378-84
0022-5223/$30.00
Copyright © 2005 by The American Asso-
ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2005.06.015
1378.e1 The Journal of Thoracic and CaObjectives: DNA hypermethylation in promoter regions has been studied for various
types of cancer. However, there is no clear evidence that shows whether methylation
status can predict long-term survival in patients with lung cancer.
Methods: We collected tissues from 72 patients with lung adenocarcinomas. The
cancer and normal lung tissues were tested for DNA hypermethylation by using
methylation-specific polymerase chain reaction. The genes investigated were
p16INK4(p16), retinoic acid receptor -promoter (RARP2), death-associated protein
kinase (DAPK), O6-methylguanine-DNA-methyltransferase (MGMT), and glutathione-
S-transferase P1 (GSTP1). The status of the DNA methylation was analyzed, and we
focused on long-term outcomes, as well as other clinical variables.
Results: DNA hypermethylation was observed in 83% for p16, 63% for RARP2,
32% for DAPK, 17% for MGMT, and 46% for GSTP1 from the cancer tissue. From
normal lung tissue, the results of methylation were positive in 75% for p16, 24% for
RARP2, 10% for DAPK, 6% for MGMT, and 33% for GSTP1. During the mean
follow-up period of 18  11 months (1-40 months), 25 (35%) patients experienced
recurrence, and 13 died. In multivariable analysis, old age (60 years, P  .007),
male sex (P  .004), unmethylation of DAPK from cancer tissue (P  .045), and
hypermethylation of RARP2 from normal tissue (P  .000) were risk factors for
poor survival. Pathologic stage (P  .023), unmethylation of DAPK from normal
tissue (P  .043), and hypermethylation of RARP2 from normal tissue (P  .030)
were risk factors for disease-free survival.
Conclusions: DNA methylation status of CpG islands seems to be a useful predictor
of long-term outcome for adenocarcinoma of the lung. However, because the
predictive power is still low, further studies, including those with multiple genes, are
necessary to increase its usefulness in the clinical setting.
Various studies have been performed to find ideal molecular markers topredict the long-term outcomes of lung cancer, such as long-term survivaland recurrence. Among these efforts, DNA hypermethylation in promoter
regions has been studied for various types of cancer. The inactivation of the tumor
suppressor gene p16INK4a (p16),1 the retinoic acid receptor -promoter gene
(RARP2),2 the DNA repair gene O6-methylguanine-DNA-methyltransferase
(MGMT),3 the detoxifying gene glutathione-S-transferase P1 (GSTP1),4 and the
death-associated protein kinase gene (DAPK)5 by promoter hypermethylation has
been well described in primary lung cancer. Our previous study demonstrated that
RARP2 and DAPK might affect the recurrence pattern in non–small cell lung
cancer (NSCLC) after surgical resection.6 However, there has been no clear evi-
dence that demonstrated correlation between methylation status and long-term
survival in patients with lung cancer.
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could be used to predict the clinical outcomes of patients
with primary adenocarcinoma of the lung after surgical
resection.
Materials and Methods
Sample Collection
Among the 653 patients who underwent surgical resection for
primary lung cancer between December 2000 and April 2004 at
Seoul National University Hospital, we selected 72 patients whose
pathologic diagnoses were adenocarcinoma and whose frozen
specimens were available from our Lung Cancer Tissue Bank.
Informed consent for tissue collection and gene analysis for re-
search purposes were obtained from individual patients preopera-
tively according to the policy of the Lung Cancer Tissue Bank,
Cancer Research Institute, Seoul National University. Twenty-nine
subjects were men, and 43 were women (mean age, 59 years;
range, 38-85 years). Ten patients were actively smoking within 3
months before the operation, and 20 were ex smokers. Forty-two
patients denied having a history of active smoking. Seven patients
received preoperative chemotherapy. Lobectomy was performed in
65 patients, pneumonectomy was performed in 6 patients, and
wedge resection was performed in 1 patient. Radical mediastinal
lymph node dissection was performed in every patient. Fifteen
patients received adjuvant chemotherapy, 17 received adjuvant
irradiation, and 1 received both treatments postoperatively. Tissue
sampling was performed immediately after lung resection. The
cancer mass was cut in half, and the tissue from the most solid part
was sampled. The normal lung tissues were obtained from the
normal-appearing portion of the lung in the resected specimen, far
apart from the cancer mass. The tissues were quickly frozen in
liquid nitrogen and stored at 80°C until analysis.
DNA Preparation and Bisulfite Modification
Genomic DNA samples from frozen lung cancer tissue were
isolated by use of the QIAmp Tissue Kit (Qiagen, Hilden, Ger-
TABLE 1. Summary of primer sequences, annealing tempe
polymerase chain reaction
Gene Forward primer (5=->3=)
p16 M: TTATTAGAGGGTGGGGCGGATCGC M:
U: TTATTAGAGGGTGGGGTGGATTGT U: C
RARP2 M: TCGAGAACGCGAGCGATTCG M:
U: TTGAGAATGTGAGTGATTTGA U: A
DAPK M: GGATAGTCGGATCGAGTTAACGTC M:
U: GGAGGATAGTTGGATTGAGTTAATGTT U: C
MGMT M: TTTCGACGTTCGTAGGTTTTCGC M:
U: TTTGTGTTTTGATGTTTGTAGGTTTTTGT U: A
GSTP1 M: TTCGGGGTGTAGCGGTCGTC M:
U: GATGTTTGGGGTGTAGTGGTTGTT U: C
RARP2, Retinoic acid receptor -promoter; DAPK, death-associated prote
S-transferase P1.many), according to the manufacturer’s protocol. One microgram
The Journal of Thoracic anof genomic DNA was digested with restriction enzyme (HindIII;
Intron Biotechnology, Kyungki-Do, Korea), and bisulfite conver-
sion was carried out with reagents provided in the CpGenome
DNA Modification Kit (Intergen, Purchase, NY).
Methylation-specific Polymerase Chain Reaction
Polymerase chain reaction (PCR) primers that distinguish between
these methylated and unmethylated DNA sequences were then
used. Primer sequences of all genes for both the methylated and
unmethylated forms, annealing temperatures, and the expected
PCR product sizes are summarized in Table 1.
Methylation-specific PCR (MSP) amplification for the 5 genes
was carried out with the hot start method by using the Qiagen
HotStart Master Mix Kit (Qiagen, Hilden, Germany). Thermocy-
cling conditions were initial denaturation and hot start at 95°C for
15 minutes, 35 cycles of denaturation at 95°C for 30 seconds,
annealing at a specific temperature for 1 minute, and extension at
72°C for 45 seconds. Normal lung tissue DNA treated in vitro with
an excess of SssI methyltransferase (New England Biolabs, Ip-
swich, Mass) was used as a positive control for methylated alleles
of each gene. Water blanks were used as a negative control.
Clinical Data
All 72 patients had follow-up visits at the clinic every 3 months.
The mean follow-up period was 18 months (range, 1-40 months).
On every visit, chest radiograms and sputum cytology examina-
tions were performed, and chest computed tomographic scans were
obtained on an annual basis. If there were any symptoms or
observations suggesting recurrence, additional evaluations, such as
bone scanning, brain magnetic resonance imaging, or positron
emission tomographic/computed tomographic scanning, were per-
formed depending on the suspected site of the recurrence.
The relationship between the clinical outcomes (overall sur-
vival and disease-free survival) and DNA hypermethylation pat-
terns were analyzed, along with clinical variables, such as sex, age,
res, and PCR product sizes used for methylation-specific
Reverse primer (5=->3=)
Annealing
temperature
(°C)
Product
size
(bp)
CCGAACCGCGACCGTAA 62 150
CCCAAACCACAACCATAA 60 151
AATCCAACCGAAACGA 59 146
AATCCAACCAAAACAA 55 146
CCCAAACGCCGA 57 98
TCCCTCCCAAACACCAA 55 106
TCTTCCGAAAACGAAACG 62 81
CCACACTCTTCCAAAAACAAAACA 59 93
CAATACTAAATCACGACG 57 91
CCCAATACTAAATCACAACA 55 97
ase; MGMT, O6-methylguanine-DNA-methyltransferase; GSTP1, glutathione-ratu
GACC
AAC
GACC
ACC
CCCT
AAA
GCAC
ACT
GCCC
CAC
in kinand pathologic TNM stage.
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The frequency of methylation in the normal tissue and the cancer
tissue was calculated for each considered gene and then tested by
using the McNemar 2 test for paired proportion differences.
Because the distribution of patients’ number in TNM stage was not
appropriate for analysis, we merged the category into early
(stage II) and late stage (stage II), and an association of
methylation with TNM stage was investigated by using the 2 test.
Overall survival and recurrence patterns were investigated by
using the Kaplan-Meier method, and the differences between
groups determined on the basis of risk factors were tested by using
the log-rank test. Cox regression analysis was used to explore the
influence of independent prognostic factors in a multivariable
model. The factors were chosen by using a stepwise forward
method with criteria for variable inclusion of 0.06 and that for
variable exclusion of 0.10.
Results
Frequency of Methylation in Lung Cancer Tissue
DNA hypermethylation was observed in 83% (60/72) for
p16, 63% (45/72) for RARP2, 32% (23/72) for DAPK,
17% (12/72) for MGMT, and 46% (33/72) for GSTP1 from
the cancer tissue. From normal lung tissue, methylation was
positive in 75% (54/72) for p16, 24% (17/72) for RARP2,
10% (7/72) for DAPK, 6% (4/72) for MGMT, and 33%
(24/72) for GSTP1 (Table E1). The frequencies of individ-
ual gene hypermethylation between cancer tissue and nor-
TABLE 2. Risk factors for long-term survival rates: Univa-
riable and multivariable analysis of various clinical factors
and gene hypermethylation
Factors
Log rank Cox regression
P value Odds ratio (95% CI) P value
Age (60 y) .1073 9.500 (1.837-49.127) .007
Sex (female) .0020 10.042 (2.116-47.667) .004
Stage (II) .0544 — —
p16
Cancer .3014 — —
Normal .5740 0.176 (0.029-1.074) .060
RARP2
Cancer .7642 — —
Normal .0002 35.559 (4.901-257.981) .000
DAPK
Cancer .0664 0.244 (0.062-0.967) .045
Normal .4118 — —
MGMT
Cancer .4454 — —
Normal .3592 — —
GSTP1
Cancer .8436 — —
Normal .0300 — —
CI, Confidence interval; RARP2, retinoic acid receptor -promoter; DAPK,
death-associated protein kinase; MGMT, O6-methylguanine-DNA-methyl-
transferase; GSTP1, glutathione-S-transferase P1.mal tissue were significantly different in RARP2, DAPK,
1378.e3 The Journal of Thoracic and Cardiovascular Surgery ● Nand MGMT. Abnormal promoter hypermethylation in at
least one gene was found in 63 (87.5%) patients at the
cancer tissue and observed in 57 (79.2%) patients at the
normal tissue. The unmethylated form of all genes, which
resulted in an unmethylated band, was detected in 100% of
the samples, suggesting coexistence with noncancer cells.
We also conducted a test for normal lung tissue from
nonsmoking benign lung disease and found no band for
methylation in each gene (Figure E1).
Clinicopathologic Correlation
Pathologic TNM stages included stage Ia in 13, stage Ib in
19, stage IIa in 0, stage IIb in 11, stage IIIa in 22, stage IIIb
in 6, and stage IV in 1 patient. Methylation frequencies of
individual genes were not associated with the TNM staging.
There were no operative deaths. During the mean follow-up
period of 18 months (standard deviation, 11; range, 1-40
months), 25 (35%) patients experienced recurrence, and 13
died. Clinical variables, such as sex, age, TNM stage, and
gene methylation patterns, were tested as to whether they
affect overall survival. When exploring each factor at a
time, male sex (P  .002), higher TNM stage (II, P 
.054), hypermethylation of RARP2 in normal tissue (P 
.000), and hypermethylation of GSTP1 in normal tissue
(P  .030) turned out to be significant variables that af-
fected poor long-term survival (Table 2 and Figure 1).
Although unmethylation of DAPK in cancer tissue seemed
to affect long-term survival, it did not result in statistical
significance (P  .066). In the Cox regression model we
considered multifactors chosen by using a stepwise forward
method. Male sex (P  .004), old age (60 years, P 
.007), unmethylation of DAPK from cancer tissue (P 
.045), and hypermethylation of RARP2 from normal tissue
(P  .000) were the risk factors for poor survival (Table 2
and Figure E2). Only advanced TNM stage (II, P  .052)
was a risk factor for disease-free survival in univariable
analysis. However, unmethylation of DAPK (P  .043)
from normal tissue and hypermethylation of RARP2 from
normal tissue (P  .030), as well as advanced TNM stage
(II, P  .023), were risk factors for disease-free survival
(Table 3 and Figure E3).
Discussion
A significant amount of time has been spent searching for
prognostic markers that predict survival for patients with
cancer. Gene-silencing events that involve transcriptional
inactivation associated with abnormally methylated pro-
moter CpG islands are a fundamental feature of human
cancer. By using MSP assays developed by Herman and
coworkers,7 the methylation status of the promoter region
for various tumor suppressor genes have been extensively
studied by many researchers. Hypermethylation of promoter
CpG islands for p16 has been reported to be a marker for
ovember 2005
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NSCLC.9,10 On the contrary, however, others reported no
significant correlation between hypermethylation for p16
and survival.11 Promoter hypermethylation of DAPK,12
fragile histidine triad (FHIT),13 Ras association domain fam-
ily 1 (RASSF1A),10,14,15 insulin-like growth factor– binding
protein 3 (IGFBP),16 and MGMT17 have been reported as
prognostic markers for NSCLC.
In the present study we demonstrated that hypermethyl-
Figure 1. Kaplan-Meier curves for overall survival according to
the methylation status for the normal tissue RARP2 (A) and the
cancer tissue DAPK (B). The numbers on the graph represent
patients remaining at risk. DAPK, Death-associated protein ki-
nase; RARP2, retinoic acid receptor -promoter.ation of RARP2 in normal tissue (P  .000) and unmethy-
The Journal of Thoracic anlation of DAPK in cancer tissue (P  .045) were significant
variables that affected long-term survival. The study of
retinoids in lung cancer dates back to seminal observations
by Wohlbach and Howe,18 who discovered that vitamin A
deprivation in cattle led to an increased incidence of lung
and upper aerodigestive tract cancers. A gradual loss of
RAR is seen in normal tissue, damaged epithelium, areas
of dysplasia, squamous cell carcinomas, and adenocarcino-
mas, which supports the hypothesis that the RAR gene
might exert tumor-suppressive effects in lung cancer. How-
ever, there are still debates regarding the role of RAR for
lung cancer development.
We had previously reported there was no significant
relationship between gene methylation and long-term sur-
vival in our series of surgically resected NSCLC.6 In that
cohort, however, unmethylation of DAPK and hypermethyl-
ation of RARP2, as well as advanced T stage and preoperative
chemotherapy, were significant risk factors for early recurrence
in the remaining lung. Interestingly, Kim and associates19
found that hypermethylation of the RARP2 gene has a dif-
ferential effect on the development of second primary lung
cancers in patients with NSCLC, depending on their smok-
ing status. Specifically, they reported second primary lung
cancer developed more frequently when RARP2 was un-
methylated than when it was hypermethylated in current
smokers. In contrast, the development of second primary
TABLE 3. Risk factors for recurrence-free survival: Univa-
riable and multivariable analysis of various clinical factors
and gene hypermethylation
Factors
Log rank Cox regression
P value Odds ratio (95% CI) P value
Age (60 y) .4207 — —
Sex (female) .0920 — —
Stage (II) .0515 2.493 (1.132-5.490) .023
p16
Cancer .5974 — —
Normal .0674 — —
RARP2
Cancer .2597 — —
Normal .0946 2.642 (1.098-6.360) .030
DAPK
Cancer .3530 — —
Normal .0943 0.121 (0.016-0.9529) .043
MGMT
Cancer .9179 — —
Normal .1507 — —
GSTP1
Cancer .8376 — —
Normal .1173 — —
CI, Confidence interval; RARP2, retinoic acid receptor -promoter; DAPK,
death-associated protein kinase; MGMT, O6-methylguanine-DNA-methyl-
transferase; GSTP1, glutathione-S-transferase P1.lung cancer in former smokers was more prevalent in pa-
d Cardiovascular Surgery ● Volume 130, Number 5 1378.e4
General Thoracic Surgery Kim et altients with hypermethylated RARP2.19 Their report sug-
gested the possible explanation for our previous result, as
well as a different effect of retinoids on survival. In this
study we did not find any correlation between the RARP2
methylation in cancer tissue and survival. Moreover, the
RARP2 methylation in cancer tissue did not show a spe-
cific pattern of recurrence in the remaining tracheobronchial
tree. The explanation for these observations is not clear. It
might be because we excluded squamous cell carcinoma,
which has been known to be more related to smoking
compared with adenocarcinoma. Our series included an
unusually high number of women and nonsmokers. It has
been suggested that adenocarcinoma in nonsmoking women
might exhibit different biologic behavior from lung cancer
in male smokers with squamous cell histology. For exam-
ple, nonsmoker female adenocarcinoma has been known to
have a higher rate of epidermal growth factor receptor
(EGFR) mutation. Indeed, in our study samples, as many as
31 (43%) patients were found to have some form of EGFR
mutation, which is a much higher rate than would be ex-
pected (unpublished data). Another reason might be because
our series did not have enough cases or an appropriate
follow-up period to demonstrate the development of second
primary lung cancer. Although we performed DNA se-
quencing of bisulfite PCR product for the RARP2 gene in
3 samples and verified correct sequences, we did not con-
duct tests for all 5 genes in every sample. The lack of
confirmatory sequencing experiments prohibited us from
being able to deny any chance of false-negative or false-
positive results, which might have affected our results.
Many researchers are investigating the methylation sta-
tus of normal tissue adjacent to the tumor.20,21 It is relevant
to think that hypermethylation of normal tissue might sug-
gest the presence of a premalignant area and might have an
effect on the prognosis. In our previous report we were
unable to find any significance between hypermethylation of
the normal tissue and long-term survival. In the present
study the hypermethylation of normal tissue RARP2 was a
clear prognostic factor for poor survival in both univariable
and multivariable analyses. We analyzed our data, stratify-
ing by smoking history. However, it did not affect the result
at all. Because our institution has a strict guide for smoking
cessation for patients who undergo lung resection, none of
our patients smoked postoperatively, and we did not have
current smokers at the time of follow-up, for whom the
methylation of RARP2 might have worked as a good
prognostic factor, as Kim and associates have suggested.19
DAPK is a proapoptotic serine-threonine kinase involved
in apoptosis. Recent experiments established that DAPK
functions as a tumor suppressor in at least 2 different stages
of tumorigenicity, namely an apoptotic checkpoint function-
ing early during cell transformation and a second one that
occurs later in cancer development (ie, during metastasis).
1378.e5 The Journal of Thoracic and Cardiovascular Surgery ● NFor lung cancer, Kim and colleagues22 reported that in-
creased tumor size, pathologic stage, and lymph node in-
volvement correlated with DAPK loss. However, others
reported that DAPK promoter methylation was detected
without any association with the stage of disease.20,23,24 Our
series did not show any correlation between DAPK meth-
ylation status and stage of cancer either. Our result is
interesting because unmethylation, instead of hypermethyl-
ation, of DAPK was a risk factor for poor survival. We do
not have an appropriate explanation for this phenomenon.
There might be another factor that causes DAPK methyl-
ation to affect survival in different ways, or it could be only
a false-positive result. Because this is the first report ana-
lyzing pure adenocarcinoma of the lung for the DAPK gene,
further study for this specific gene is mandatory. Another
explanation can be addressed on the basis of statistical
analysis method. We primarily used a conventional 5%
significance level for each test. However, we might also
need to consider a more conservative significance level for
the univariable Cox regression analysis, considering a pos-
sible chance effect to find a significant result caused by
multiple testing. If we use a 1% significance level, most of
the candidate factors turn out to be nonsignificant, but
hypermethylation of RARP2 in normal tissue would still
be a highly significant predictor of overall survival, whereas
DAPK would not. We also note the limited size of this study
and that associations identified might have occurred by
chance. Therefore the findings suggested should be inter-
preted with caution and in a less conclusive but exploratory
way. Although we were not able to demonstrate the func-
tional mechanism, we observed that the search for the DNA
methylation status of CpG islands in both cancer tissue and
adjacent normal tissue showed promise as a predictor of
long-term outcome for adenocarcinoma of the lung. How-
ever, because the predictive power is still low, further
studies, including those with multiple genes, are necessary
to increase its usefulness in the clinical setting.
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Discussion
David S. Schrump (Bethesda, Md). Dr Kim, I would like to
congratulate you on a very elegant study.
The Journal of Thoracic anSimilar to other neoplasms, lung cancers exhibit a DNA meth-
ylation paradox, which is manifested as a derepression of multiple
imprinted genes, upregulation of cancer-testis antigens, and a
paradoxical inactivation of tumor suppressor genes. The fact that
not all of the imprinted alleles or the cancer-testis antigens are
upregulated and that the tumor suppressor genes are not simulta-
neously repressed during malignant transformation suggests that
the mechanisms underlying the methylation paradox are extremely
complex.
A number of tumors, including colorectal carcinomas and leu-
kemias, exhibit a methylation profile (methylator phenotype) that
seems to correlate with patient outcome. To date, a methylator
phenotype has not been identified in lung cancers. Published
studies from numerous laboratories, including our own, demon-
strate considerable heterogeneity regarding gene-expression pro-
files among different patients with lung cancer.
In your study you examined the methylation status of 5 genes
that are commonly methylated in human lung cancers. This work
appears to extend your previous studies pertaining to methylation
analysis of 4 of these genes, namely p16, RAR, DAPK, and
methylguanine-methyltransferase in 61 patients with lung cancer.
In that study DNA methylation was not associated with any
clinicopathologic characteristics and did not appear to coincide
with patient survival. In that study you demonstrated that unmethy-
lation of DAPK in the tumor and hypermethylation of RAR in
normal tissues coincided with increased risk of recurrence. In the
current study involving 72 patients with adenocarcinomas, you
have substantiated your previous findings. In all likelihood, the
phenomenon might indicate that the inhibition of apoptotic path-
ways is not contingent on methylation of DAPK. Furthermore, the
methylation of RAR in the normal tissues might actually be a
surrogate marker of more profound epigenetic changes that are
relevant in the tumor itself.
I have several questions concerning this article. The methyl-
ation analysis that you performed involved methylation-specific
PCR techniques, which have been fairly well standardized; how-
ever, there are some difficulties with this technique, particularly in
terms of analysis of primary tumor specimens because of the
kinetics of the PCR reactions and false-positive, as well as false-
negative, results. Whereas the frequency of methylation of DAPK
observed in your study was consistent with that seen in reported
studies, the methylation frequencies for the other 4 genes were
considerably higher than typically reported in the literature. To
date, there has been no significant difference in the methylation
status of these genes in squamous versus adenocarcinoma histol-
ogy. Could you comment or speculate as to why the frequency of
methylation was so much higher in your study relative to what has
been reported in the literature with patients who were also from
Asia.
Dr Kim. For the first question, that is one of the problems we
have with the MSP method in terms of a high possibility of having
a false-positive rate. It can happen because it is a PCR that has a
high false-positive rate. Also, if the bisulfite modifications happen
to be insufficient, we will have a false-positive rate as well. Our
previous study showed that there was a high frequency of MGMT
methylation compared with that of the current study. To decrease
the false-positive rate, we changed our primers and the PCR
conditions. However, we discovered that our population had a
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General Thoracic Surgery Kim et alrelatively high frequency of methylation, especially for p16. This
result might possibly be related to ethnic differences. For example,
for EGFR mutation, Asian persons have been known to have a
higher frequency of mutation. In conclusion, one possibility might
be a false-positive result, and the other might be related to ethnic
differences.
Dr Schrump. Were any of the PCR results confirmed by
bisulfite sequencing, once again to get at the issue of either
false-positive or false-negative results here?
Dr Kim. We have been doing the PCR sequencing, and it is
consistent at least for RAR. I personally think that the more
important thing is immunohistochemistry to explain the mecha-
nism of carcinogenesis. Histone deacetylation is likely one of the
mechanisms of controlling functional expression. However, meth-
ylation results do not consistently match with the immunohisto-
chemistry in our experience.
Dr Schrump. I have 2 other brief questions. Do you have
any insight regarding the K-ras mutation status of these tumors?
As you know, K-ras mutations have been associated with ab-
errant methylation of certain genes. Also, have you observed
any association between smoking exposure and particular meth-1378.e7 The Journal of Thoracic and Cardiovascular Surgery ● NDr Kim. This population is made up of patients with adeno-
carcinoma, and more than 50% of the patients were women;
women generally do not smoke in Korea. Additionally, I stratified
the patients according to smoking status but could not find any
difference. Regarding the K-ras mutation, I have been working on
it with the same cohort of patients. We found about 20% of the
patients had mutations for K-ras, but we have not matched those
data with this study.
Dr Schrump. Forty-three of the 72 patients in the present study
had early-stage tumors (stage I or stage II). As we look at methy-
lator phenotypes in more advanced tumor stages, nodal status
emerges as the predominant predictor of prognosis and survival.
Have you had an opportunity or do you intend to return to your
data to analyze specifically the early-stage tumors? Conceivably,
patients with these tumors did not receive adjuvant chemotherapy
or radiation that might have confounded your analysis.
Dr Kim. That finding is research I would like to continue in the
future. Unfortunately, the study population is small in the present
study, and stratifying a limited population for early lung cancer
might not be possible. However, because we have been collecting
our specimens since 1996, we might be able to perform that kind
of analysis in the future.ylation profiles? Dr Schrump. I congratulate you on an excellent study.ovember 2005
Kim et al General Thoracic SurgeryTABLE E1. Frequency of methylation in 72 tissue samples of adenocarcinoma of the lung
Gene
Frequency of methylation (%) P value*
Lung cancer tissue Normal lung tissue
p16 60 (83%) 54 (75%) .238
RARP2 45 (63%) 17 (24%) .000
DAPK 23 (32%) 7 (10%) .000
MGMT 12 (17%) 4 (6%) .039
GSTP1 33 (46%) 24 (33%) .064
RARP2, Retinoic acid receptor -promoter; DAPK, death-associated protein kinase; MGMT, O6-methylguanine-DNA-methyltransferase; GSTP1, glutathione-
S-transferase P1. *P values were calculated by using the McNemar 2 test for paired proportion differences.
Figure E1. Representative methylation-
specific polymerase chain reaction prod-
uct of the promoter for p16, RARP2,
DAPK, MGMT, and GSTP1 in tumor and
normal tissue from patients with adeno-
carcinoma of the lung (A) and the result in
normal tissue from nonsmoking patients
with benign lung disease (B). The pres-
ence of product in lane M indicates the
presence of methylated genes; the pres-
ence of product in lane M indicates the
presence of unmethylated genes.DAPK,
Death-associated protein kinase; GSTP1,
glutathione-S-transferase P1; H2O, water
control; IVM, in vitro methylated control;
MGMT, O6-methylguanine-DNA-methyl-
transferase; Nor, normal tissue; Normal,
nonsmoking benign patients; Patient, pa-
tient with adenocarcinoma; RARP2, reti-
noic acid receptor -promoter; Tum, tu-
mor tissue; U, unmethylation.The Journal of Thoracic and Cardiovascular Surgery ● Volume 130, Number 5 1378.e8
General Thoracic Surgery Kim et alFigure E2. Cox regression cumulative hazard function for overall survival according to the methylation status for
the normal tissue RARP2 (A) and the cancer tissue DAPK (B). DAPK, Death-associated protein kinase; RARP2,
retinoic acid receptor -promoter.1378.e9 The Journal of Thoracic and Cardiovascular Surgery ● November 2005
Kim et al General Thoracic SurgeryFigure E3. Cox regression cumulative hazard function for disease-free survival according to methylation status for
the normal tissue RARP2 (A) and DAPK (B). DAPK, Death-associated protein kinase; RARP2, retinoic acid
receptor -promoter.The Journal of Thoracic and Cardiovascular Surgery ● Volume 130, Number 5 1378.e10
